ClinicalTrials.gg
RecruitingNCT05465629Updated Jan 29, 2025

Viome Nutritional Programs to Improve Clinical Outcomes for Gastrointestinal Conditions

An interventional study of VIOME Precision Nutrition Program and VIOME-designed condition-based supplements in Gastrointestinal Health, sponsored by Viome. Recruiting at 1 site in United States. Open to participants aged 25 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-29.

Sponsored by Viome · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
25 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 292 studies in Nausea with a site in United States — 31 open to participants now, 34 under way, 8 of them phase 3. Nausea · United States.

Planned enrollment
77th of 262
150 · median 86
Started
2022
with 11 others
No phase
103 of 292
13 open now
Primary completion
2026-12
later than 7 of 33 live
Registered
261st of 292
by date

Among the 292 studies in Nausea with a site in United States, this one is the 77th largest by planned enrollment of the 262 interventional ones that give a count, is one of 12 that started in 2022, is one of 103 with no phase, reaches primary completion later than 7 of the 33 other live ones, and was the 261st registered.

Nausea

646 studies on the registry are indexed under Nausea; 87 are open to participants now.

Browse Nausea studies →

Open to participants now

31 of the 292 studies in Nausea with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Nausea studies recruiting now, 23 (43%) set no upper age limit and 19 (36%) stop at 75 or younger; 10 take children under 18; 13 take healthy volunteers.

This study: 25 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 292 studies in Nausea with a site in United States, or all of them as a file.
02

Study summary

US residents who have gastrointestinal issues sign the informed consent form and are screened and enrolled for this study. Participants who are enrolled complete a survey upon enrollment and are randomized into one of three arms. This study is direct to participant and will NOT utilize clinical sites.

Read the detailed description

Participants who meet the eligibility criteria are randomized into any of the three arms including: the control arm, VIOME's condition-based supplements (VCS) arm or the VIOME Precision Nutrition Program (VPNP) arm.

Placebo, Viome-designed condition-based supplements and Viome's Precision Nutrition Program include supplements, may include dietary recommendations towards improving the symptoms associated with gastrointestinal wellness. The trial will last approximately 4 months for each participant.

03

Conditions studied

  • Gastrointestinal Health

Keywords

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Bloating
  • Gastroesophageal
  • Viome
  • Nutrition
  • Supplements
  • VPNP
  • Viome precision nutrition program
  • Reflux
  • Diet
  • Microbiome
  • Biome
  • Gastrointestinal
04

Who can participate

Ages eligible
25 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Resident of the United States
  • Females and males ages 25-75 (inclusive)
  • Able to speak and read English
  • No unexplained weight loss, fevers, anemia, or blood in stool
  • Willing and able to follow the trial instructions, as described in the recruitment letter
  • Signed and dated prior to any trial-specific procedures.
  • Diagnosis of IBS according to ROME IV criteria AND IBS-SSS score of 125-450 (inclusive)

Exclusion criteria

Exclusion criteria

  • Unwilling to change current diet
  • Prior use of Viome products or services
  • Antibiotic use in the previous 4 weeks
  • Women who are pregnant (current or planned in the next 4 months), or breastfeeding
  • \< 90 days postpartum
  • Active infection
  • Unable or unwilling to use Viome's App on an iPhone or Android smartphone
  • Significant diet or lifestyle changes in the previous 1 month
  • IBD diagnosis
  • Use of drugs, products or devices within 1 month prior to and 4 months after the start of the trial
  • Cancer therapy within the previous 1 year
  • Major surgery in the last 6 months or planned in the next 4 months
  • Prescribed any drug(s) that may interact with the supplement formulations
  • Have any medical condition or allergy that may interact with, or prevents the healthy consumption of the supplements
  • Allergies to any study-specific supplement ingredients
  • Currently on a specific diet:

FODMAP KETO PALEO

  • Gastrointestinal disease including: Esophagitis Celiac disease GI or obstruction Peptic ulcer Duodenal or gastric ulcer disease
  • GI surgery except:

Appendectomy and benign polypectomy

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
150 participants (estimated)

Study arms

  • No intervention
    Placebo

    Participants who have gastrointestinal issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.

  • Active comparator
    Viome's Precision Nutrition Program

    Participants who have gastrointestinal issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.

    Combination Product: VIOME Precision Nutrition Program

  • Active comparator
    Viome's condition-based supplements

    Participants who have gastrointestinal issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.

    Dietary Supplement: VIOME-designed condition-based supplements

Interventions

  • Combination productVIOME Precision Nutrition Program

    Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.

    Also known as: VPNP

  • Dietary supplementVIOME-designed condition-based supplements

    Pre-formulated supplements based on overall health conditions. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.

    Also known as: VCS

06

What researchers measure

Primary outcomes

  1. Efficacy of VIOME's designed condition based supplements (VCS)

    Number of participants that show an improvement in GI health compared to baseline survey assessment.

    Time frame: ~4 months

  2. Efficacy of VIOME Precision Nutrition Program (VPNP)

    Number of participants that show an improvement in GI health compared to baseline survey assessment.

    Time frame: ~4months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Dec 2026, 49 months after the start.

Of 126 interventional studies with no phase under Nausea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 49 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2022
First posted
Jul 20, 2022
StartActual
Nov 18, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05465629
Lead sponsor
Viome
Responsible party
Sponsor
First posted
Jul 20, 2022
Start date
Nov 18, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 29, 2025

Study contacts

Mory Mehrtash
Contact
studies@viome.com
(425) 300-6933
Momchilo Vuyisich
Contact
studies@viome.com
(425) 300-6933
Momchilo Vuyisich
principal investigator · Viome

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion